Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences

Rhea-AI Summary

Impel NeuroPharma (NASDAQ: IMPL) announced that CEO Adrian Adams will participate in two upcoming investor conferences. The Cowen & Co. 42nd Annual Health Care Conference will feature a fireside chat on March 7, 2022, at 1:30 p.m. ET, while the Oppenheimer 32nd Annual Healthcare Conference will include a company presentation on March 17, 2022, at 2:40 p.m. ET. Investors can access a live webcast and a 90-day replay on the company's website. Impel specializes in therapies for high unmet medical needs, focusing on the central nervous system.

SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, will participate in the following upcoming investor conferences.

Cowen & Co. 42nd Annual Health Care Conference
Format: Fireside Chat
Date: Monday, March 7, 2022
Time: 1:30 p.m. ET

Oppenheimer 32nd Annual Healthcare Conference
Format: Company Presentation
Date: Thursday, March 17, 2022
Time: 2:40 p.m. ET

A live webcast of the event will be available on the Investors section of the Impel NeuroPharma website at https://investors.impelnp.com/. A replay of the presentation will be available on the website for 90 days.

About Impel NeuroPharma
Impel NeuroPharma, Inc. is a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. Impel offers and is developing treatments that pair its proprietary Precision Olfactory Delivery (POD^®) technology with well-established therapeutics. In addition to Trudhesa™ (dihydroergotamine mesylate) nasal spray, which is approved in the United States for the acute treatment of migraine with or without aura in adults, Impel is also developing INP105 for the acute treatment of agitation and aggression in patients with autism, and INP107 for OFF episodes in Parkinson’s disease.

Contact:

Media Relations:
Melyssa Weible
Elixir Health Public Relations
Phone: (1) 201-723-5805
Email: mweible@elixirhealthpr.com 

Investor Relations
Christina Tartaglia
Stern Investor Relations
Phone: 212-362-1200
Email: christina.tartaglia@sternir.com

FAQ

What is the date of the Cowen & Co. 42nd Annual Health Care Conference for Impel NeuroPharma?

The Cowen & Co. 42nd Annual Health Care Conference will take place on March 7, 2022.

When will Adrian Adams be presenting at the Oppenheimer 32nd Annual Healthcare Conference?

Adrian Adams will present at the Oppenheimer 32nd Annual Healthcare Conference on March 17, 2022, at 2:40 p.m. ET.

How can investors access the live webcast of Impel NeuroPharma's presentations?

Investors can access the live webcast of Impel NeuroPharma's presentations on the Investors section of their website.

What are the main focuses of Impel NeuroPharma's therapies?

Impel NeuroPharma focuses on developing therapies for diseases with high unmet medical needs, particularly in the central nervous system.

What technology does Impel NeuroPharma use for its therapies?

Impel NeuroPharma uses its proprietary Precision Olfactory Delivery (POD®) technology in its therapies.